Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …

Glioblastoma (WHO grade IV astrocytoma) is the most frequent primary brain tumor in adults,
representing a highly heterogeneous group of neoplasms that are among the most …

Standard treatment for glioblastoma multiforme is surgery followed by radiotherapy and
chemotherapy, generally with temozolomide. However, disease recurs in almost all patients …

Simple Summary This review describes in a very detailed and exhaustive approach the
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …

Since its inception in 2000, metronomic chemotherapy has undergone major advances as
an antiangiogenic therapy. The discovery of the pro-immune properties of chemotherapy …

Simple Summary Glioblastoma is one of the most treatment-refractory human malignancies,
and despite techniques that have allowed scientists and clinicians to better understand the …

Metronomic chemotherapy, continuous and dose‐dense administration of chemotherapeutic
drugs with lowered doses, is being evaluated for substituting, augmenting, or appending …

The progression of glioblastomas is associated with a variety of neurological impairments,
such as tumor-related epileptic seizures. Seizures are not only a common comorbidity of …

Glioma is the most frequent and aggressive type of brain neoplasm, being anaplastic
astrocytoma (AA) and glioblastoma multiforme (GBM), its most malignant forms. The survival …

This systematic review assesses current molecular targeted therapies for glioblastoma
multiforme (GBM), a challenging condition with limited treatment options. Using PRISMA …